Author:
ÖKSÜZ Ersoy,BUĞDAY M. Serdar,ACUN DELEN Leman,ÇAĞAŞAR Ozlem,DEMİR Bilgehan,AKTAŞ İbrahim,SİANANOĞLU Muhammet,ALTINTOP GEÇKİL Ayşegül,AYDOGAN BAYKARA Rabia,ALADAĞ Hülya,GÜNEŞ Ajda,AKTÜRK Erdal,PEMBEGÜL İrem
Publisher
Van Yuzuncu Yil University
Reference22 articles.
1. Ankit B.P. COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers What Is the Evidence? JAMA.2020;1:1-2.
2. Awadhesh Kumar Singh, Akriti Singh, Altamash Shaikh, Ritu Singh, Anoop Misra. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2020;14 (3): 241-246.
3. Cao B, Wang Y, Wen D, Liu, W, Wang J, Fan G, Ruan, Song B, Cai Y, Wei M, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N. Engl. J. Med. 2020; 7;382(19):1787-1799.
4. Chakraborty A.R, Sharma G, Sharma, Bhattacharya M, Lee S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. European Review for Medical and Pharmacological Sciences. 2020; 24: 4016-4026.
5. Chaolin Huang, Yeming Wang, Xingwang Li, Lili Ren, Jianping Zhao, Yi Hu, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 6736: 1 – 10.